April 16, 2018 - Orgenesis, Inc. (NASDAQ:ORGS) has filed a financial statement reporting Common Stock Shares Outstanding of $13,300,676 USD. Previously, on July 17, 2018, Orgenesis, Inc. reported Common Stock Shares Outstanding of $13,300,676 USD. This represents a change of 0.00% in Common Stock Shares Outstanding.

Period EndPeriodValue
2017-11-30 2017-Q4 13,300,676
2018-05-31 2018-Q2 13,300,676
2016-11-30 2016-Q4 9,508,068
2015-02-28 2015-Q1 55,970,565
2014-08-31 2014-Q3 55,172,617
2014-05-31 2014-Q2 54,244,914
2014-02-28 2014-Q1 53,147,276
2013-08-31 2013-Q3 51,144,621
2013-05-31 2013-Q2 51,144,621
2013-02-28 2013-Q1 49,617,903
2012-08-31 2012-Q3 49,117,903
2012-05-31 2012-Q2 48,617,903
2012-02-29 2012-Q1 48,517,903
2014-11-30 2014-Q4 55,970,565
2013-11-30 2013-Q4 51,144,621
2012-11-30 2012-Q4 49,117,903
2011-11-30 2011-Q4 80,500,000
2010-11-30 2010-Q4 80,500,000
2015-11-30 2015-Q4 55,835,950
2018-02-28 2018-Q1 10,273,301
CostOfRevenue DeferredRevenueCurrent GeneralAndAdministrativeExpense IncomeTaxExpenseBenefit IncreaseDecreaseInDeferredRevenue IncreaseDecreaseInPrepaidExpense InterestExpenseShortTermBorrowings OtherNonoperatingIncomeExpense PrepaidExpenseCurrent ResearchAndDevelopmentExpense Revenues ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroMbrFourRynTkMKW ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroNKyFourtrSbNEightcT ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroOnenFivedvBmbCPZerob ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroQJEightQHEightvKrPTQ ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroSixVScnTyThreeEightTNX ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroSrrhxFiveEightxbQlSeven ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroTHSevenFkNTWyFourCJ ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroTwoFivefSixggwbHLHk ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroVpvvmTwoFiveHMcck ScheduleOfFinancialExpensesZeroThreeEightFourZeroZeroZpQmcvvcRzmFour ScheduleOfFinancialExpensesZeroThreeEightFourZeroZerohdRbGVtSixGOneWh ScheduleOfFinancialExpensesZeroThreeEightFourZeroZerozHFouryNxKThreeFFourGb ScheduleOfIntangibleAssetsFutureAmortizationExpenseZeroThreeEightFourZeroZeroFourGqHKpPHOnevrG ScheduleOfIntangibleAssetsFutureAmortizationExpenseZeroThreeEightFourZeroZerobTsKmSevenvVKScB ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroFourLMfQFcMBTXZero ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroddPFTwolPmTSixHN ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerofpdTgJEightdrKRS ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerolDpQDOneTZeroFMTwoNine ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroshmKPlBDJbtFour ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZerovGLmQlmNSixZerokT ScheduleOfResearchAndDevelopmentExpensesZeroThreeEightFourZeroZeroxZtEighttqXtPlFV ScheduleOfRevenueZeroThreeEightFourZeroZeroEightNineXwREightzvFiveThreeTd ScheduleOfRevenueZeroThreeEightFourZeroZeroEightwpCFourTwomFFourhgEight ScheduleOfRevenueZeroThreeEightFourZeroZeroKcwVnhZeroNzMtFour ScheduleOfRevenueZeroThreeEightFourZeroZerotttPFiveZRhCOneJr ScheduleOfRevenueZeroThreeEightFourZeroZeroyfmEightcBSMkcgFive ScheduleOfRevenueZeroThreeEightFourZeroZerozMThreeSixFkqmgSsR ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTJtWLZNZClFk ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTSevenMKgxCThreeWFourDFour ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroTwoNNinexFivegWDTRsl ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroXlsBMSevenvEightOnenrM ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZerofKFivexOneFiveybTfps ScheduleOfRevenuesFromMajorCustomersZeroThreeEightFourZeroZeroxTwoNqFourrgKbJFourThree StockBasedCompensationExpensesRelatedToOptionsGrantedToEmployeesAndDirectors

Related News Stories

Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline

2018-06-03 seekingalpha
Overlooked specialty contract development and manufacturing stock in the exciting field of advanced cell therapy with a potential for an exponential upside. (184-3)

CUSIP: 68619K105